TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02628886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid
Description: pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo 0.9% sodium chloride plus tetanus toxoid
Description: pregnant women will be given intramuscular saline injection between 28-34 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tetanus toxoid
Description: new born babies will be given PCV13 vaccine at birth
Study: NCT02901977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Antihypertensive therapy
Study: NCT01702376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban 800 mg
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
Study: NCT02455557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02901977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Antihypertensive therapy
Study: NCT05251610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg oral propranolol and oxytocin
Description: Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin only
Description: Participants will have outright augmentation or induction of labor with oxytocin
Study: NCT01791270

Intervention type: DEVICE
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. - Respiratory Polygraphy~2. - Ambulatory Blood Pressure Monitoring~3. - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. - ß1en subunit expression in peripheral blood leukocytes.
Study: NCT01328379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER 5mg
Description: 5mg, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER 10mg
Description: 10mg, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, twice daily
Study: NCT02735785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing Online Peer Education (HOPE) Social Media Intervention
Study: NCT02500576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IVPB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02450240

Intervention type: BEHAVIORAL
Intervention: self-report questionnaires

Intervention type: BEHAVIORAL
Intervention: self-report questionnaires

Intervention type: BEHAVIORAL
Intervention: behavioral tasks

Intervention type: BEHAVIORAL
Intervention: behavioral tasks

Intervention type: BEHAVIORAL
Intervention: behavioral tasks

Intervention type: BEHAVIORAL
Intervention: behavioral tasks

Intervention type: OTHER
Intervention: physiological measurements

Intervention type: OTHER
Intervention: physiological measurements

Intervention type: OTHER
Intervention: physiological measurements

Intervention type: OTHER
Intervention: physiological measurements

Intervention type: OTHER
Intervention: structural and functional magnetic resonance imaging and EEG

Intervention type: OTHER
Intervention: structural and functional magnetic resonance imaging and EEG

Intervention type: OTHER
Intervention: structural and functional magnetic resonance imaging and EEG

Intervention type: OTHER
Intervention: structural and functional magnetic resonance imaging and EEG

Intervention type: OTHER
Intervention: biomarker and microbiome assessments

Intervention type: OTHER
Intervention: biomarker and microbiome assessments

Intervention type: OTHER
Intervention: biomarker and microbiome assessments

Intervention type: OTHER
Intervention: biomarker and microbiome assessments
Study: NCT02450240

Intervention type: OTHER
Intervention: blood to derive induced pluripotent stem cells

Intervention type: OTHER
Intervention: blood to derive induced pluripotent stem cells

Intervention type: OTHER
Intervention: blood to derive induced pluripotent stem cells

Intervention type: OTHER
Intervention: blood to derive induced pluripotent stem cells

Intervention type: OTHER
Intervention: genetic and epigenetic assessments

Intervention type: OTHER
Intervention: genetic and epigenetic assessments

Intervention type: OTHER
Intervention: genetic and epigenetic assessments

Intervention type: OTHER
Intervention: genetic and epigenetic assessments
Study: NCT00671411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound with intravenous microbubble contrast injection
Description: Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney.
Study: NCT00599222

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TTT
Description: Transpupillary thermotherapy (TTT)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham TTT
Description: Sham Transpupillary thermotherapy (TTT)
Study: NCT02396264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: 50 pcos women will be assigned to normocaloric mediterranean diet for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normocaloric diet
Description: 50 pcos women will be assigned to standardized normocaloric diet for 6 months
Study: NCT01774227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The pops-titration group
Description: The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The slow-coagulation group
Description: The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
Study: NCT00193726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab Premarin (Ethinyl estradiol)
Description: Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 5 days prior to each cycle of chemotherapy
Study: NCT02500576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Given IV
Study: NCT02455557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT01565785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The FSM-DPI.
Description: Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
Study: NCT02564042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study: NCT02455557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO or IV
Study: NCT02290158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Finishing Protocol
Description: Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
Study: NCT00293761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost, Investigational
Description: One drop in study eye once daily for 13 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost (TRAVATAN)
Description: One drop in study eye once daily for 13 days
Study: NCT03510195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDICORP HO PREPARATORY MODULE
Description: 3 DAY course module to prepare medical graduates to become house officers
Study: NCT01046292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba
Description: The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
Study: NCT03451422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Study: NCT02500576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Given IV
Study: NCT04094142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission.
Study: NCT02981407

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Transfusion of packed red blood cell units

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Transfusion of packed red blood cell units
Study: NCT01913665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B.lactis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inulin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B.Lactis +Inulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01276444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swan-Ganz catheter
Description: the data s=derived from PAC included pulmonary artery occlusion pressure etc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transpulmonary thermodilution + central venous saturation
Description: Described in details above
Study: NCT00610441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04511117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: ProTaper Next rotary system and iRoot SP sealer with composite restorations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrown group
Description: ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
Study: NCT02388594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZFN Modified CD4+ T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZFN Modified CD4+ T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03655327

Intervention type: OTHER
Intervention: reach to grasp a cup
Description: reach to grasp a cup of different weights located at different heights of table

Intervention type: OTHER
Intervention: reach to grasp a cup
Description: reach to grasp a cup of different weights located at different heights of table
Study: NCT01628614

Intervention type: OTHER
Intervention: Standard of Care
Description: Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
Study: NCT02590822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cambridge Weight Plan
Description: Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Sessions
Description: The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.
Study: NCT04937335

Intervention type: OTHER
Intervention: intratumoral hemorrhage
Description: Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
Study: NCT03594916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
Study: NCT02564042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically
Study: NCT02742584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Stress Test
Description: Varying bladder volumes during cough stress test.
Study: NCT03555812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic inclination measurement
Description: Measurement of pelvic inclination per ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic inclination measurement
Description: Measurement of pelvic inclination per ultrasound
Study: NCT03158506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: \[14C\]-labelled HMS5552
Study: NCT01752699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
Study: NCT03744026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoCloud-9
Description: Escalating numbers of ultrasound beams at constant acoustic pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose of carboplatin infusion is AUC4-6
Study: NCT00635700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: 20-160 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04365543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia
Description: Please see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Relaxation Therapy (PRT)
Description: Please see arm/group descriptions
Study: NCT01336530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxetacaine, aluminium and magnesium hydroxide
Description: 20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxetacaine
Description: 20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium and aluminium hydroxide
Description: 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
Study: NCT03387943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
Study: NCT04424992

Intervention type: OTHER
Intervention: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.
Description: Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.